AstraZeneca Pharma India Limited

ASTRAZEN.NS

Drug Manufacturers - Specialty & Generic · Healthcare

Exchange

National Stock Exchange of India

Winston Score

Winston is serious

Mixed quality — meaningful strengths and weaknesses.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Good

Growth

Good

Cash Flow

Weak

Stability

Exceptional

Valuation

Weak

Dividends

Good

Track this stock — start free trial

Winston Score History

The full picture

AstraZeneca Pharma India Limited is the Indian subsidiary of AstraZeneca PLC, a global British-Swedish pharmaceutical company. It sells prescription medicines in India across key therapy areas including oncology, cardiovascular disease, diabetes, and respiratory conditions. The company markets drugs to hospitals, clinics, and doctors across India, with products like Tagrisso (lung cancer) and Farxiga (diabetes) among its key offerings.

The company earns revenue primarily by selling branded prescription medicines to healthcare providers and distributors across India. It benefits from the backing of its global parent, which gives it access to a strong pipeline of patented drugs that generic competitors cannot easily copy. AstraZeneca PLC operates in over 100 countries and generates roughly $45 billion in annual global revenue, making it one of the largest pharmaceutical companies in the world. The key growth driver for the Indian subsidiary is rising healthcare spending and growing diagnosis rates for chronic diseases in India, though currency risk and regulatory pricing controls remain ongoing challenges.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+21.2% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-23.0% YoY

YoY Growth Rate

Earnings declining

Insider Activity

81.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

₹0 cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

AstraZeneca Pharma India Limited is a rare growth stock that's already generating positive cash flow while growing at 21%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

22.1%

Thin — 22.1% gross margin

Profit after running costs

Operating Margin

6.4%

Modest — 6.4% operating margin

Return on the money invested

ROCE

24.0%

Exceptional — 24.0% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+31.3%

Fast-growing sales (+31.3% YoY)

Profit growth

EPS YoY

-7.5%

Earnings shrinking (-7.5% YoY)

Slight earnings drop. Typical near a cyclical low.

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

-39%

Weak — only -39% of profit becomes cash

Spare cash per sale

FCF Margin

-2.7%

Burning cash (-2.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.02

Conservative — low debt load (0.02)

Covers its interest

Interest Cover

37.17x

Comfortably covers interest (37.2x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

109.3x

no trend

Expensive — P/E 109.3

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

-136.4

SLOWING

Earnings expected to fall — forward P/E higher than today

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

0.44%

no trend

Small dividend — 0.44% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

+730.8%

no trend

Dividend growing fast (730.8% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial